페녹시벤즈아민 하이드로클로라이드

그림문자(GHS)

• 그림문자(GHS)

  

• 신호 어

  Warning

• 유해·위험 문구

  H302：삼키면 유해함

  H351：암을 일으킬 것으로 의심됨 (노출되어도 암을 일으키지 않는다는 결정적인 증거가 있는 노출경로가 있다면 노출경로 기재)

• 예방조치문구

  P201：사용 전 취급 설명서를 확보하시오.

  P308+P313：노출 또는 접촉이 우려되면 의학적인 조치· 조언를 구하시오.

페녹시벤즈아민 하이드로클로라이드 MSDS

• 2-(N-Benzyl-2-chloroethylamino)-1-phenoxypropane hydrochloride

페녹시벤즈아민 하이드로클로라이드 화학적 특성, 용도, 생산

• 개요

  Phenoxybenzamine hydrochloride (dibenzyline) is an orally effective, long-acting non-selective (alpha1 and alpha2) alpha-adrenoceptor blocking agent. It is used for the control of episodes of hypertension associated withpheochromocytoma. It literally produces a "chemical sympathectomy". It increases blood flow to the skin, mucosa and abdominal viscera, and lowers both supine and erect blood pressures. It has no effect on the parasympathetic system. The initialdose is 10 mg/day, increased by 10 mg every 4 days till the desired response is attained.The usual dosage range is 20-60mg/day.

• 화학적 성질

  white crystalline solid or powder. Odorless. soluble in ethanol, chloroform, propylene glycol, slightly soluble in benzene, slightly soluble in cold water. The melting point of its free base is 38-40 ° C, and it is soluble in benzene.

• 용도

  Phenoxybenzamine (5.0 to 60.0 mg/day) is used in order to control episodes of hypertension and sweating, it has a relatively slow onset and prolonged effect when compared to alternative α-blockers. If tachycardia is excessive, it may also be necessary to use a betablocker concomitantly. In addition, phenoxybenzamine has been tested for its efficacy in micturition disorders resulting from neurogenic bladder, functional outlet obstruction, and partial prostatic obstruction.

• 일반 설명

  Phenoxybenzamine hydrochloride is a white crystalline powder. Melting point 137.5-140°C. Used as an antihypertensive drug.

• 공기와 물의 반응

  Light sensitive and may be sensitive to exposure to air . Insoluble in water.

• Mechanism of action

  Phenoxybenzamine hydrochloride is a noncompetitive alpha-adrenergicreceptor blocker, and its action cannot be nullified by increasing the amount of agonist, or agonists. It causes epinephrine reversal in that the administration of epinephrine after pretreatment with phenoxybenzamine elicits vasodilation, and, conversely, phenoxybenzamine reverses epinephrine-mediated vasoconstriction to vasodilation. It may inhibit neuronal and extraneuronal uptake mechanisms of norepinephrine. At higher concentrations, it inhibits responses to 5-HT, histamine and acetylcholine.

• Clinical Use

  Oral phenoxybenzamine is used for the preoperativemanagement of patients with pheochromocytoma and in thechronic management of patients whose tumors are notamenable to surgery. Only about 20% to 30% of an oraldose is absorbed.

• 부작용

  The adverse effects of phenoxybenzamine include nasal congestion, miosis, postural hypotension, tachycardia, and inhibition of ejaculation.

• Safety Profile

  Confumed carcinogen with experimental carcinogenic and teratogenic data. Poison by intraperitoneal,intravenous, and subcutaneous routes. Human systemic effects by ingestion: changes in tubules, including acute renal failure, acute tubular necrosis. Moderately toxic by ingestion. Other experimental reproductive effects. Mutation data reported. A long-acting adrenergic blocker. When heated to decomposition it emits very toxic fumes of NOx and Cl-.

• Carcinogenicity

  Phenoxybenzamine hydrochloride is reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in experimental animals.

• Dosage

  Initially, 10 mg of Dibenzyline (phenoxybenzamine hydrochloride) twice a day. Dosage should be increased every other day, usually to 20 to 40 mg 2 or 3 times a day, until an optimal dosage is obtained, as judged by blood pressure control.

페녹시벤즈아민 하이드로클로라이드 준비 용품 및 원자재

페녹시벤즈아민 하이드로클로라이드 공급 업체

Global(282)Suppliers

페녹시벤즈아민 하이드로클로라이드 관련 검색